MALIGNANT MELANOMA

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. About 674 adults took part. The goal was to see if the combination helps stop cancer from growing longer and impro…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. The trial included 131 Chinese participants who had not received prior treatment for their advanced disease. Res…

This early-phase trial tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several types of advanced cancer. The idea is that L-NMMA may remove a brake on the immune system, helping pembrolizumab work better. Only 12 adults took part, and …

This early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study looked at 30 people with melanoma who were taking BRAF/MEK inhibitor drugs. The goal was to see how often these drugs cause retinal changes (MEKAR) and what those changes look like. Participants had regular eye exams before, during, and after treatment to track any vis…

This study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in tumor tissue and blood could predict how well they would respond to first-line immunotherapy drugs. Researchers also explored whether gut bacteria play a role i…

This study looked at 14 adults with melanoma who were taking a combination of BRAF and MEK inhibitors. Researchers wanted to understand eye changes (retinopathy) that can happen as a side effect of this treatment. They used regular eye exams and imaging to track these changes ove…